The skeleton is the most common metastatic site for breast cancer, with bone metastasis causing pain as well as risk of pathological fractures. Interaction between tumors and the bone microenvironment creates a vicious cycle that accelerates both bone destruction and cancer progression. This study is the first to analyze the soluble factors secreted by breast tumor-associated osteoblasts (TAOBs), which are responsible for promoting cancer progression. The addition of CXCL5 (chemokine (C-X-C motif) ligand 5), present in large amounts in TAOB-condition medium (TAOB-CM), mimicked the inductive effect of TAOB-CM on breast cancer epithelial-mesenchymal transition, migration and invasion. In contrast, inhibition of CXCL5 in OBs decreased TAOBmediated cancer progression. Inducement of MCF-7 and MDA-MB-231 cancer progression by TAOB-derived CXCL5 is associated with increased Raf/MEK/ERK activation, and mitogen-and stress-activated protein kinase 1 (MSK1) and Elk-1 phosphorylation, as well as Snail upregulation. Activation of Elk-1 facilitates recruitment of phosphorylated MSK1, which in turn enhances histone H3 acetylation and phosphorylation (serine 10) of Snail promoter, resulting in Snail enhancement and E-cadherin downregulation. Moreover, mice treated with anti-CXCL5 antibodies showed decreased metastasis of 4T1 breast cancer cells. Our study suggests that inhibition of CXCL5-mediated ERK/Snail signaling is an attractive therapeutic target for treating metastases in breast cancer patients.
INTRODUCTION
The skeleton is the most common metastatic site for breast cancer, with bone metastasis developing in 65-75% of patients with metastatic breast cancer. Bone metastasis causes pain as well as increases the risk of pathological fractures. 1, 2 The interaction between tumors and the bone microenvironment is a vicious cycle that increases both bone destruction and tumor progression: the tumor secretes soluble factors to stimulate osteoclastogenesis, and the bone stroma produces growth factors to enhance tumor progression.
1,2 Metastasis, the major cause of death for cancer patients, is a complex and multistep process in which secondary cancers are formed in other nonadjacent organs. 3, 4 The development of metastasis includes several steps that consists of cellular transformation and abnormal growth, new blood or lymphatic vessels formation, dissemination of tumor cells into the circulation, attachment to the target organs and growth in target sites. 3, 5 The migratory and invasive ability of cancer cells is required in many of these steps, and is therefore associated with metastasis.
Epithelial-mesenchymal transition (EMT) is a common phenotypic transformation in cancer cells that causes loss of cellcell adhesion and increases cell motility, [6] [7] [8] thereby increasing their metastatic potential. Snail, one of the important transcription factors involved in the regulation of EMT, acts by repressing the expression of the E-cadherin gene. 9 A recent study has demonstrated that the Ras/Raf/ERK cascade modulates Snail expression, leading to EMT in various cell types. 10 Phosphorylation of transcription factor Elk-1 by extracellular signal-regulated kinases 1 and 2 (ERK1/2) translocates it to the nucleus and then regulates serum response element-dependent transcription by chromatin remodeling. 11 Mitogen-and stressactivated protein kinases (MSKs), another downstream target of ERK signaling pathway, play regulatory roles in chromatin remodeling. 12 Therefore, we hypothesized that Raf/MEK/ERK may play a pivotal role in mediating the progression of breast cancer by Snail upregulation via MSK1/Elk-1-mediated epigenetic regulation.
Chemokines, a multifunctional family of small cytokine-like proteins, selectively control the recruitment and migration of lymphocytes to infection or injury sites by chemoattraction. 13, 14 Recent evidence increasingly shows that chemokines also play a critical role in neoplastic transformation and cancer progression, in addition to their role in development and inflammatory responses. 15, 16 Although regulation of bone metastasis has been the focus of intensive investigation, relatively little is known about how osteoblasts influence the tissue specificity of metastasis and progression of breast cancer, or precisely which molecules are involved in the cross-talk of osteoblasts and cancer cells in the tumor microenvironment. Understanding the mechanisms implicated in the interaction between cancer and osteoblasts is essential for the development of biomarkers of metastasis, as well as for the development of more effective therapies. The aim of this study was to determine whether inflammatory CXCL5 (chemokine (C-X-C motif) ligand 5) secreted by tumor-associated osteoblasts 1 induces cancer migration and invasion through the interaction between tumors and the bone microenvironment, and whether ERK/MSK/Elk-1 is involved in the regulation of an oncogenic transcription factor Snail by epigenetic regulation. Our investigations have enhanced our understanding of the crosstalk between osteoblasts and breast cancer via CXCL5 in the metastasis of breast cancer cells, providing a molecular basis explaining the vicious cycle between osteoblasts and breast cancer cells.
RESULTS

TAOBs increased breast cancer migration and invasion
Soluble factors released from the bone matrix may be involved in the progression of cancer. 17, 18 To investigate this hypothesis, we collected breast tumor-associated osteoblast culture medium (TAOB-CM), and then assessed the effects of TAOB-CM on breast cancer cell proliferation, migration and invasion (Supplementary Figure S1A) . As shown in Figures 1a and b , both MCF-7-OB-CM (20%) and MDA-MB-231-OB-CM (20%) increased migration and invasion of MCF-7 and MDA-MB-231 cells but did not affect cell proliferation in either cell line (Supplementary Figure S1B) . In addition, MCF-7-OB-CM and MDA-MB-231-OB-CM also caused MCF-7 and MDA-MB-231 to undergo EMT, including the downregulation of epithelial marker (E-cadherin), and upregulation of fibroblast markers (N-cadherin and vimentin) (Figure 1c ).
CXCL5 plays an important role in TAOB-mediated cancer progression We found that TAOBs express large amounts of CXCL5 protein ( Figure 1d ). Next, we determined the effect of CXCL5 on the proliferation, migration, invasion and EMT of MCF-7 and MDA-MB-231 cells. As shown in Supplementary Figure S1C , after 48 h of treatment of the two cancer cell lines, CXCL5 did not increase cell proliferation in either MCF-7 or MDA-MB-231 cells, but did enhance the migration and invasiveness of MCF-7 and MDA-MB-231 cells (Figures 1e and f) . In addition, CXCL5 also caused MCF-7 and MDA-MB-231 cells to undergo EMT, including the downregulation of epithelial marker (E-cadherin), and upregulation of fibroblast markers (vimentin and N-cadherin) (Figure 1g ).
To further elucidate the nature of the soluble factors present in the sera of breast cancer patients, we examined the levels of CXCL5 in healthy donors, stage I and stage III patients. The average CXCL5 serum level in the sera of 15 stage III patients was 124.3 pg/ml, whereas the levels of CXCL5 in the sera of healthy donors and stage I patients were lower than those found in stage III patients (Figure 2a ). MCF-7 cells were used to assess cell migration and invasion in the presence of 15% of the serum from breast cancer patients. As shown in Figures 2b and c, migration and invasion of MCF-7 cells was dramatically enhanced in the presence of patients' sera. Sera presenting high levels of CXCL5 exhibited greater enhancement of cell migration (Figure 2d ). Our results convincingly prove that patients with invasive breast cancer have soluble factors released from the bone into the sera, which effectively increases cancer cell migration and invasion.
To better understand the role of CXCL5, we blocked the effect of CXCL5 on MCF-7 and MDA-MB-231 migration and invasion by using CXCL5-specific receptor (CXCR2) neutralization antibody. As shown in Figure 3a , both MCF-7 and MDA-MB-231 express detectable levels of CXCR2. The migration and invasion of MCF-7-OB-CM and MDA-MB-231-OB-CM in MCF-7 and MDA-MB-231 cells was neutralized by treatment with anti-CXCR2 antibody, but not by isotype control (Figures 3b and c) . In addition, anti-CXCR2 antibody decreased the stimulatory effects of the chemotaxin CXCL5 in breast cancer cell migration and invasion (Figures 3d and e) . Similarly, depletion of CXCL5 by immunoprecipitation from MCF-7-OB-CM and MDA-MB-231-OB-CM also reduced the migration and invasion of MCF-7 and MDA-MB-231 cells (Figures 3f and g ).
Furthermore, MCF-7 cells were neutralized by treatment with anti-CXCR2 antibody, preventing the induction of cell migration and invasion via the sera of breast cancer patients (Figures 3h and i) . These data suggest that the migration and invasion of MCF-7 and MDA-MB-231 induced by CXCL5 is dependent on CXCR2 receptors.
To evaluate the contribution of CXCL5 to the induction of MCF-7-CM-and MDA-MB-231-CM-associated osteoblasts in cancer progression, we interfered with the effects of CXCL5 by short hairpin RNA (shRNA) transfection. Compared with nontarget shRNA-transfected osteoblasts, CXCL5 shRNA effectively decreased CXCL5 expression in osteoblasts by 80%, as determined by realtime PCR and enzyme-linked immunosorbent assay (ELISA; Supplementary Figure S2A ). Knockdown of CXCL5 by shRNA from osteoblasts was sufficient to reverse the effect of MCF-7-CM and MDA-MB-231-CM on the induction of breast cancer migration and invasion (Supplementary Figures S2B and C).
TAOB-CM and CXCL5 activate ERK/MSK1/Elk and increase the expression of Snail Previous studies have shown that CXCL5 stimulates cancer progression through ERK1/2. 19 Consequently, we assessed the effect of TAOB-CM and CXCL5 on mitogen-activated protein kinase cascade expression. The results showed that exposure of MCF-7 and MDA-MB-231 cells to TAOB-CM or CXCL5 resulted in the phosphorylation of Raf, MEK1/2 and ERK1/2 and MSK1 ( Figure 4a ). On the other hand, the expression of Raf, MEK1/2 and ERK1/2 (unphosphorylated form) was unaltered by TAOB-CM or CXCL5 treatment in either MCF-7 or MDA-MB-231 cells. In addition, the downstream factors of ERK1/2, MSK1 and Elk-1 were activated via phosphorylation and subsequently translocated from the cytosol into the nuclei after TAOB-CM and CXCL5 treatment (Figures 4a and b) .
We next investigated the role of ERK1/2 on TAOB-CM-and CXCL5-mediated activation of MSK1 and Elk-1, as well as on cell migration and invasion. Transfection of MCF-7 and MDA-MB-231 cells with ERK2 shRNA reduced the phosphorylation of ERK2 induced by TAOB-CM and CXCL5 (Figure 4c ). Selective genetic inhibition of ERK abrogated TAOB-CM-and CXCL5-mediated MSK1 and Elk-1 phosphorylation in cancer cells (Figure 4c ). In addition, specific knockdown of ERK2 expression by ERK2 shRNA decreased cell migration and invasion in TAOB-CM-and CXCL5-treated cells (Figures 4d and e) . These data suggest that ERK1/2 is the upstream event of MSK1 and Elk-1, which are involved in TAOB-and CXCL5-mediated cancer progression.
Snail is involved in TAOB-CM-and CXCL5-mediated EMT and cell progression Snail has been reported to decrease E-cadherin expression by means of transcription repression, inducing EMT and cell migration.
6,9 Consequently, we assessed whether TAOB-CM and CXCL5 caused EMT, migration and invasion through Snail. Immunoblot data show that TAOB-CM and CXCL5 increase Snail levels while decreasing the expression of E-cadherin in both MCF-7 and MDA-MB-231 cells (Figures 5a, 1c and g ). We next investigated the role of Snail on TAOB-CM-and CXCL5-mediated cell migration and invasion by shRNA transfection. As shown in Figure 5b , in comparison with control shRNA, Snail shRNA reduced Figure 3 . Neutralizing CXCL5-specific receptor by its specific CXCR2 antibody decreased TAOB-CM-mediated cancer progression. (a) The expression of CXCR2. CXCR2 antibody decreased the effect of TAOB-CM on cell migration (b) and invasion (c). CXCR2 antibody decreased the induction of CXCL5 on cell migration (d) and invasion (e). Depletion of CXCL5 from TAOB-CM decreased the induction of TAOB-CM on cell migration (f ) and invasion (g). CXCR2 antibody decreased the effect of breast cancer patients' sera on cell migration (h) and invasion (i). Depletion of CXCL5 was performed by CXCL5 antibody, followed by immunoprecipitation techniques. Breast cancer cells seeded in upper inserts were treated with or without CXCR2 antibody (5 mg/ml) or immunoglobulin G (IgG; 5 mg/ml), and TAOB-CM (20%), breast cancer patient sera (15%), CXCL5 (10 nM) or CXCL-5 depletion. TAOBs were added into lower wells to act as a chemoattractant agent for 24 h. The invasiveness and migration ability of MCF-7 and MDA-MB-231 cells were quantified by QCM 24-well Cell Migration and Invasion assay. Each value is the mean±s.d. of three independent experiments. The asterisk indicates a significant difference with the control, as analyzed by analysis of variance (ANOVA) with Student's t-test post hoc (*Po0.05). All experiments were performed independently at least 3 times.
Snail expression by B70%. Inhibition of Snail by shRNA transfection blocks the TAOB-CM-and CXCL5-mediated downregulation of E-cadherin in cancer cells (Figure 5c ). On the other hand, ERK1/2 phosphorylation was unaltered by TAOB-CM and CXCL5 treatment in either Snail-knockdown MCF-7 or MDA-MB-231 cells. In contrast, selective genetic inhibition of ERK2 abrogated TAOB-CM-and CXCL5-mediated Snail upregulation and E-cadherin downregulation in cancer cells (Figure 5d ). These data suggest that Snail is an upstream factor of E-cadherin but not of ERK1/2. Furthermore, Snail shRNA also decreased TAOB-CM-and CXCL5-mediated cancer cell migration and invasion (Figures 5e and f).
MSK1 cooperates with Elk-1 to regulate the expression of Snail by histone acetylation and phosphorylation Activated MSK1 has been reported to associate with Elk-1, and then to increase the expression of the cancer invasion-related gene by enhancing the phosphorylation and acetylation of histone H3. 20 We Figure 6a , TAOB-CM and CXCL5 increased the association of MSK1 with Elk-1. Chromatin immunoprecipitation assay also verified that Elk-1 bound to the promoter of Snail at the À 438 to 388 region after TAOB-CM and CXCL5 treatment (Figure 6b ). Acetylation and phosphorylation of histone H3 on the Elk-1-binding region of Snail promoter was thereby increased (Figure 6b ). In addition, inhibition of Elk-1 by specific shRNA transfection decreases the upregulation of TAOB-CM and CXCL5 on Snail expression (Figure 6c ). Acetylation and phosphorylation of histone H3 on the Elk-1-binding region of Snail promoter was also abrogated by ElK-1 shRNA (Figure 6d) . Inhibition of MSK1 also reduces the upregulation of Snail expression by TAOB-CM and CXCL5 in MCF-7 and MDA-MB-231 cells (Figure 6e ). Acetylation and phosphorylation of histone H3 on the Elk-1-binding region of Snail promoter was also abrogated by MSK1 shRNA (Figure 6f ). These data suggest that MSK1/Elk-1 cooperation is involved in the regulation of Snail transcription.
CXCL5 increases breast cancer metastasis in vivo
We next used animal experiments to determine the role of CXCL5 in breast cancer metastasis in mice. Mouse breast cancer cell line 4T1 was injected into the mammary fat pads in mice, and then the cells were allowed to spontaneously metastasize from a primary tumor in vivo. Before 4T1 transplantation, we assessed whether CXCL5 increases the ability of 4T1 in migration, invasion and EMT. As shown in Figures 7a and b , CXCL5 increased migration and invasion of 4T1 cells. CXCL5 also caused 4T1 cells to undergo EMT, including the downregulation of epithelial marker (E-cadherin), and upregulation of fibroblast markers (vimentin and N-cadherin) (Figure 7c ). These data coincide with human breast cancer data. ELISA data show that the sera obtained from 4T1-bearing mice revealed high levels of CXCL5 compared with the sera of control mice ( Figure 7d) .
Next, we assessed whether CXCL5 increases the metastasis of 4T1 cells. Treatment of mice by CXCL5 (0.5 mg/kg) increased the metastasis of 4T1 cells in 100% (8 of 8) of the mice, in comparison with 75% (6 of 8) of the control mice. Tumor nodules in various organs (livers, lungs and intestines) of the CXCL5-treated mice were both more numerous and larger than those found in the control group of mice (Figures 7e-g ). Mice treated with CXCL5 also contained larger metastatic nodules in lungs, livers and intestines than the lungs of the control mice.
Finally, we assessed whether inhibiting CXCL5 decreases the metastasis of cancer. Treatment of mice by anti-CXCL5 monoclonal antibody inhibited the metastasis of 4T1 cells in 62.5% (5 of 8) of the mice, in comparison with 100% (8 of 8) of the control mice. The tumor nodules in various organs (livers, lungs and intestines) of the CXCL5 antibody-treated mice were far fewer than those found in the control group mice (Figures 7h-j) .
DISCUSSION
Bone metastasis has permitted the identification of factors, produced by the tumor cells themselves or by the microenvironment in response to the tumor, that mediate the process of bone destruction. 21 This study is the first to investigate the interaction between tumors and the bone microenvironment that results in tumor progression. TAOB-CM, or invasive breast cancer patient sera containing high levels of CXCL5, also significantly increase the migration and invasion of breast cancer cells. Pretreatment of breast cancer cells with CXCL5-specific CXCR2 neutralization antibody decreases TAOB-CM or invasive breast cancer patient sera-mediated cancer cell migration and invasion, suggesting that CXCL5 may be a major factor enhancing the metastatic ability of breast cancer cells.
EMT has been characterized as a dynamic and reversible biological behavior. When cancer cells escape from the primary site by the circulation and metastasize at secondary sites by switching epithelial phenotype into mesenchymal phenotype, these cancer cells may return to an epithelial phenotype at secondary sites. [22] [23] [24] EMT, described by a conversion in the cell type-specific protein pattern and promotion of cell movement, is vital for the generation of new tissue types during embryonic development, and plays a critical role in inflammatory response and wound healing of adult tissue. 25 It has also been implicated in important steps of cancer development, such as invasion and metastasis. 26 Ectopic expression of Snail has been reported to be a sufficient activator of EMT, as well as being a predictor for an aggressive malignancy. 27, 28 In breast cancer, increased Snail expression has been associated with lymph node involvement, invasiveness and metastatic potential, [28] [29] [30] and also with decreased rates of recurrence-free survival. 30 Knockdown of Snail by RNA interference in MDCK-Snail cells induces a complete MET, associated with the increase of E-cadherin, decrease of mesenchymal markers and inhibition of invasiveness. 27, 31 Furthermore, inhibition of endogenous Snail leads to a notable decrease of in vivo tumor growth, accompanied by enhanced tumor differentiation and reduced invasiveness. 27 In our study, we found that treating MCF-7 and MDA-MB-231 cells with TAOB-CM or CXCL5 dramatically increases Snail expression, accompanied by the decrease of the epithelial marker E-cadherin and increase of mesenchymal markers vimentin and N-cadherin, suggesting that the interaction between the tumor and the bone microenvironment induces EMT of cancer. Selective inhibition of Snail by shRNA decreased the effects of TAOB-CM-and CXCL5-mediated E-cadherin downregulation, and cancer cell migration and invasion, suggesting that the upregulation of Snail plays a critical role in TAOB-CMand CXCL5/ENA78-mediated cell migration and EMT in breast cancer.
Compared with normal tissue or benign lesions, ERK activity is increased in invasive breast carcinomas. [32] [33] [34] As invasive cancer cells are migratory, it is reasonable to postulate that the enzymatic ERK activity could be involved in cancer cell migration. 35 Chen et al. 32 suggest that the ERK pathway regulates breast cancer cell migration by maintaining Snail expression. We found that treatment of MCF-7 and MDA-MB-231 cells treated with TAOB-CM or CXCL5 resulted in increased phosphorylation of mitogenactivated protein kinase cascade (Raf, MEK1/2 and ERK1/2). Furthermore, inhibition of ERK with ERK2 shRNA completely abrogated TAOB-CM-and CXCL5-mediated cell migration, invasion and Snail upregulation, whereas Snail shRNA did not affect the phosphorylation of ERK1/2. These data suggest that Raf/ MEK1/2/ERK1/2 signaling is the major upstream event of Snail.
ERKs are well known to activate several transcription factors and co-activators by phosphorylation, and thus to regulate specific gene expressions by controlling epigenetics and transcription dynamics. 17, 36 Transcription factor Elk-1 is phosphorylated (activated) by ERKs and recruited to the serum response elements of target gene promoter. Activated Elk-1 exhibits transcriptional activation through the formation of a complex with co-activators. The recruitment of ElK-1 and MSK1 has been reported to regulate the expression of c-fos and egr-1 stimulated by mitogens, and this transcriptional stimulation correlates with histone H3 acetylation and phosphorylation. 37, 38 Our data are the Taken together, our findings provide the first evidence that TAOB-derived CXCL5 reinforces breast cancer cell migration and invasion. Our results also clearly establish that ERK/MSK1/Elk-1 regulates Snail expression by epigenetic regulation, and enhances cancer progression ability (Figure 8 ). Neutralization of CXCL5 by CXCL5 antibody significantly decreases the incidence of cancer development in mice. This novel finding could elucidate the interaction between tumor cells and the osteoblast microenvironment, which results in a vicious cycle accelerating the malignancies of late-stage breast cancer patients. These findings on the interaction of cancer cells and osteoblasts provide important insights into the biology of tumors, and establish new rationales for using anti-CXCL5 strategies to target metastasis in breast cancer.
MATERIALS AND METHODS
Cell cultures and condition medium
Human primary osteoblasts were obtained from Lonza (Walkersville, MD, USA) and cultured in Osteoblast Growth Media. MCF-7 human breast adenocarcinoma cells (ATCC HTB-22) were cultured in Minimum Essential Medium (MEM; Life Technologies, Inc., Grand Island, NY, USA) with nonessential amino acids, 0.1 mM sodium pyruvate, 10 mg/ml insulin and 10% fetal bovine serum MDA-MB-231 human breast adenocarcinoma cells (ATCC HTB-26) and the 4T1 mouse breast cancer cell line (CRL-2539) were cultured in MEM and RPMI-1640 (Life Technologies, Inc) supplemented with 10% fetal bovine serum. To obtain the MCF-7 and MDA-MB-231-conditioned medium (CM), 2 Â 10 6 cells were seeded in a 100-mm dish and cultivated for 24 h. MCF-7 tumor-associated osteoblasts (MCF-7-OBs) and MDA-MB-231-OBs were generated by culturing human osteoblasts presenting in MCF-7-CM and MDA-MB-231-CM. After washing, the medium was replaced and the supernatants harvested after 24 h of incubation. The results were designated as MCF-7-OB-conditioned medium (MCF-7-OB-CM) and MDA-MB-231-OB-CM (Supplementary Figure S1A) . CXCL5 was neutralized using anti-CXCR2 antibody (5 mg/ml, clone 48 311, R&D Systems, Minneapolis, MN, USA). CXCL5 depletion from MCF-7-OB-CM and MDA-MB-231-OB-CM was performed using anti-CXCL5 antibodies (2 mg/ml, Ab9802; Abcam, Cambridge, MA, USA) and Sepharose A/G beads following regular immunoprecipitation techniques. Cytokine depletion was confirmed by CXCL5 ELISA assay kit.
Cell proliferation
Cells were plated in 96-well culture plates. After 24 h of incubation, the cells were treated with vehicle control-CM, various condition media or various concentrations of CXCL5 (R&D Systems Europe, Abingdon, UK) for 72 h. At the end of the assay period, cell proliferation was measured by WST-1 assay. Cell proliferation was determined by Premixed WST-1 Cell Proliferation Reagent (Clontech Laboratories Inc., Mountain View, CA, USA) in accord with the manufacturer's instructions.
Cell migration and invasion assay
Cell migration and invasion assay was conducted using QCM 24-well Cell Migration and Invasion Assay kits (Millipore Corp., Bedford, MA, USA). Briefly, cells were seeded into the migration chamber, and control medium, various condition media or various concentrations of CXCL5 were added to the bottom wells for 24 h as chemoattractant. At the end of the treatment, the cells were poststained with CyQuant GR dye in cell lysis buffer for 15 min at room temperature. Fluorescence of the migrated and invaded cells was then read using a fluorescence plate reader at excitation/ emission wavelengths of 485/520 nm.
Measurement of secreted factors
Human primary osteoblasts were treated with MCF-7-CM or MDA-MB-231-CM for 24 h. After washing, the supernatants were collected. CXCL5 levels were then assessed by CXCL5 ELISA kit. 
Immunoblot/immunoprecipitation
Cells were treated with MCF-7-OB-CM (20%), MDA-MB-231-OB-CM (20%) or 10 nM CXCL5 for the indicated times and then lysed by M-PER solution on ice for 15 min. Cell lysate was centrifuged at 14 000 g for 15 min, and the supernatant fraction collected for immunoblot. Equivalent amounts of protein were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (10-12%) and transferred to polyvinylidene difluoride membranes. After blocking for 1 h in 5% nonfat dry milk in Tris-buffered saline, the membranes were incubated with the desired primary antibody for 1-16 h. The membranes were then treated with appropriate peroxidaseconjugated secondary antibody, and the immunoreactive proteins detected using an enhanced chemiluminescence kit (Amersham, Buckinghamshire, UK) according to the manufacturer's instructions. The primary antibodies used in this study to target unphosphorylated and phospho-ERK proteins, vimentin, N-cadherin and E-cadherin, were obtained from Cell Signaling Technology (Danvers, MA, USA). Snail antibody was obtained from Abcam, Ltd (Cambridge, UK). b-Actin and glyceraldehyde-3-phosphate dehydrogenase were obtained from Upstate Biotechnology (Lake Placid, NY, USA).
Real-time reverse transcriptase-PCR RNA isolation was performed using the TRIzol reagent (Invitrogen, Carlsbad, CA, USA). Complementary DNA was prepared using an oligo (dT) primer and reverse transcriptase (Takara, Shiga, Japan) following standard protocols. Real-time PCR was performed using SYBR Green on the ABI 7500 Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). Each PCR reaction mixture contained 200 nM of each primer, 10 ml of 2 Â SYBR Green PCR Master Mix (Applied Biosystems), 5 ml complementary DNA and RNase-free water, with a total volume of 20 ml. The PCR reaction was carried out with a denaturation step at 95 1C for 10 min, and then for 32 cycles at 95 1C for 15 s and 60 1C for 1 min All PCRs were performed in triplicate and normalized to internal control glyceraldehyde-3-phosphate dehydrogenase mRNA. Relative expression was presented using the 2 -nnCT method. Gene knockdown by shRNA Knockdown of CXCL5, Snail, ERK2, MSK1 and Elk-1 was performed using the lentiviral expression system provided by the National RNAi Core Facility (Taipei, Taiwan). The lentiviruses were produced by co-transfecting HEK293T with pLKO-AS2, pLKO-AS2-CXCL5, pLKO-AS2-Snail, pLKO-AS2-ERK2, pLKO-AS2-MSK1 or pLKO-AS2-Elk-1 shRNA and two packaging plasmids (pCMVVDR8.91 and pMD.G). The efficacy of shRNA plasmids was assessed by real-time PCR and ELISA.
Chromatin immunoprecipitation
Chromatin immunoprecipitation was performed by Agarose ChIP Kit (Pierce, Rockford, IL, USA). Immunoprecipitated DNA was analyzed by quantitative PCR (Light Cycler, as described above) using SYBR Green dye.
The primers used were 5 0 -GCTTCCTCCCCAGTGATGT-3 0 and 5 0 -TCAGAAGC GCTCAGACCAC-3 0 for Snail, yielding a 171-bp fragment.
The in vivo orthotropic tumor metastasis 4T1 cells (1 Â 10 5 ) were injected into the mammary fat pads of 8-week-old female BALB/c mice. CXCL5 (0.5 mg/kg) was administered by intraperitoneal injection three times every 3 days after transplantation. Animals were killed on day 24 after 4T1 transplantation, and the number of tumor nodules in all organs of these mice was recorded for analysis of metastasis incidence. For CXCL5 inhibition, isotype control immunoglobulin G and CXCL5 neutralization antibody (50 mg/mice, clone 61 905, R&D Systems) were administered every 7 days via intraperitoneal injection three times after administration of 4T1. Animals were killed on day 24 after 4T1 transplantation and the numbers of tumor nodules in the various organs Figure 7 . CXCL5 increases the metastasis of breast cancer in vivo. CXCL5 increases migration (a), invasion (b) and EMT (c) in 4T1 cells. (d) Levels of CXCL5 in the sera of mice. (e) CXCL5 increased the number of tumor nodules in the organs. CXCL5 increased metastasis, as revealed by photographs (f ) and hematoxylin and eosin (H&E) staining (g). Neutralization of CXCL5 decreased the occurrence of 4T1 metastasis, as revealed by the number of tumor nodules (h), photographs (i) and H&E staining (j). Invasiveness and migration ability of 4T1 cells was quantified by QCM 24-well Cell Migration and Invasion assay. CXCL5 (10 nM) was used as chemoattractant for cancer migration and invasion. 4T1 cells were treated with CXCL5 (10 nM) for 24 h and the expression of various proteins assessed by immunoblot. 4T1 cells were injected into the mammary fat pads of mice. Mice were treated every 3 days with intraperitoneal (i.p.) injections of phosphate-buffered saline (PBS; n ¼ 8) or CXCL5 (0.5 mg/kg; n ¼ 8). For CXCL5 inhibition, 4T1 was injected into the fat pads of mice, and then mice were treated every 7 days with i.p. injections of immunoglobulin G (IgG; n ¼ 7) or CXCL5 antibodies (50 mg/mice; n ¼ 8). After 24 days, organs were harvested, cut and H&E stained, and then analyzed by microscopy. The number of tumor nodules in various organs was recorded for analysis of cancer incidence. The asterisk indicates a significant difference with the control, as analyzed by analysis of variance (ANOVA) with Student's t-test post hoc (*Po0.05). T, tumor. Arrows indicate tumor nodules. Figure 8 . Proposed interactions between cancer and TAOBs. Breast cancer increases osteoblasts' secretion of high levels of CXCL5, which in turn enhances the ability of breast cancer cell migration, invasion and EMT. TAOB-derived CXCL5 triggers Raf/MEK/ERK and recruitment of the Elk-1 and MSK1, which in turn enhance transcription of Snail, a repressor of E-cadherin.
